British Biotech Firm To Sell COVID-19-Focused Unit For $10M
British biotech company Roquefort Therapeutics PLC said Thursday that it has agreed to sell its COVID-19-focused subsidiary to Pleiades Pharma Ltd. for at least $10 million three years after its acquisition....To view the full article, register now.
Already a subscriber? Click here to view full article